Abstract
After technical strategies for using plants to produce vaccines, monoclonal antibodies (mAbs), or other therapeutic or protective proteins and glycoproteins improved during the past decade, enthusiasm for these newer approaches grew because the products are proving effective, according to several proponents of this technology who spoke during the 2014 ASM Biodefense and Emerging Diseases Meeting, held last January in Washington, D.C.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.